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ecent reports have highlighted the imbalance
between rising costs in drug discovery and the produc-
tion of new molecular entities for the market,
1,2 leading
to a long-term loss of efficiency.Remarkably,this decline
in productivity has occurred despite the fact that bio-
medical research benefits from large governmental and
private investments, and despite the comprehensive
improvements in our knowledge of human genes result-
ing from large sequencing projects.
The tremendous efforts that have to be invested for
drug target identification, follow-up validation studies,
and clinical trials, in combination with the high failure
rate as a consequence of individual response to drugs,
has imposed high costs on the development of drugs.
Understanding individual response to a drug, what
determines its efficacy and tolerability in the patient’s
body,is the major bottleneck in drug development and
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Understanding individual response to a drug—what determines its efficacy and tolerability—is the major bottleneck in
current drug development and clinical trials. Intracellular response and metabolism, for example through cytochrome P-
450 enzymes, may either enhance or decrease the effect of different drugs, dependent on the genetic variant. Microarrays
offer the potential to screen the genetic composition of the individual patient. However, experiments are “noisy” and
must be accompanied by solid and robust data analysis. Furthermore, recent research aims at the combination of high-
throughput data with methods of mathematical modeling, enabling problem-oriented assistance in the drug discovery
process. This article will discuss state-of-the-art DNA array technology platforms and the basic elements of data analysis
and bioinformatics research in drug discovery. Enhancing single-gene analysis, we will present a new method for inter-
preting gene expression changes in the context of entire pathways. Furthermore, we will introduce the concept of sys-
tems biology as a new paradigm for drug development and highlight our recent research—the development of a mod-
eling and simulation platform for biomedical applications. We discuss the potentials of systems biology for modeling the
drug response of the individual patient.     
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body,each individual reacts differently in terms of intra-
cellular response and metabolism.A prominent exam-
ple is seen with the cytochrome P-450 enzymes, a fam-
ily of drug-metabolizing enzymes that may either
enhance or decrease the effect of different drugs,
dependent on the genetic variant.
3 Thus, the individual
genetic composition of the patient has become a major
issue in studying drug targets and responses to medical
treatment.
Microarrays are the state-of-the-art platform for screen-
ing the genetic composition of the individual patient.This
technology offers the chance to acquire the complete
state of gene expression
4-6 and to identify genes and path-
ways that are affected by the treatment.
7,8 On the other
hand,high-throughput technologies such as microarrays
are also a part of the problem. The new technologies
have led to an increasing amount of heterogeneous (and
often conflicting) data,corresponding to an increasing
amount of potential drug targets.
Microarray experiments are “noisy”by nature,and must
be accompanied by solid and robust data analysis com-
ponents. This task has been part of bioinformatics
research since the advent of this new discipline. The
components of microarray analysis range from low-
level analysis,explorative statistics to higher-level analy-
sis involving additional data,annotation,and knowledge
in order to embed the gene expression data in a func-
tional context.The main purpose of data analysis is to
filter the information and to enrich the level of infor-
mation complexity from single gene markers to biolog-
ical pathways.
This article will discuss the state-of-the-art deoxyribonu-
cleic acid (DNA) array technology platforms and the
basic elements of data analysis and bioinformatics
research in drug discovery,developed by us and others.
Apart from the single-gene analysis we will present a
new method for interpreting gene expression changes in
the context of the pathways involved.Recent microarray
applications for neuroscience will be considered,and the
particular challenges for gene expression analysis of the
brain will be discussed.Furthermore,we will introduce
the concept of systems biology as a new paradigm for
drug development and highlight our recent research—
the development of a modeling and simulation platform
for biomedical applications.This research field, which
shows great potential for modeling the drug response of
the individual patient,will deliver valuable hypotheses
for personalized drug treatment and therapy monitoring
in the medium to long term.
DNA array platforms for 
gene expression profiling
DNA arrays are the most common gene expression pro-
filing technology.A DNA array consists of a solid sup-
port (nylon membrane, glass chip) that carries DNA
sequences representing genes—the probes.In hybridiza-
tion experiments with the target sample of labeled com-
plementary ribonucleic acids (cRNAs) and through sub-
sequent data capture a numerical value, the signal
intensity, is assigned to each probe. Labeling is done
either radioactively (phosphorus,
33P) and detected with
a phosphor imager or fluorescently (Cy3/Cy5 dyes) and
detected with specific scanners.Chips are typically small
(<2 cm
2) and allow the immobilization of tens of thou-
sands of different gene representatives.
The most prominent DNA array technology is the
Affymetrix GeneChip system.
9 Here, genes are repre-
sented by probe sets of short oligonucleotides (typically
11 to 20 25mers) that are distributed across their
sequences.These oligonucleotides are synthesized in a
highly specific manner at defined locations using a pho-
tolithographic procedure.After hybridization,the mea-
sured intensity for the represented gene is summarized
across the different probes in the probe set.Affymetrix
chips have emerged as the pharmaceutical standard,and
are widely in use because of the highly standardized chip
generation process.Whole-genome chips are available
for a large number of organisms,such as human,mouse,
rat,bovine,pig,etc.An experiment with Affymetrix tech-
nology is typically a single-channel experiment,ie,only
one target sample is analyzed in one experiment.
State of the art
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Selected abbreviations and acronyms
AD Alzheimer’s disease
ALS amyotrophic lateral sclerosis
DRPLA dentatorubral-pallidoluysian atrophy
GEO gene expression omnibus
GO gene ontology
GPCR G-protein-coupled receptor
HD Huntington's disease
PCR polymerase chain reaction
PD Parkinson’s disease
SAGE serial analysis of gene expression
SOP standard operating procedureAn alternative technology is the Agilent system.
10This
relies on the immobilization of longer oligonucleotides
(60mers) synthesized in situ at or near the surface of the
slide by inkjet printing using phosphoramidite chemistry.
These probes are highly specific for the represented gene
and show,generally,better hybridization properties than
systems with shorter oligonculeotides.Experiments are
typically double-channel experiments,ie,two target sam-
ples are analyzed simultaneously,each labeled with a dif-
ferent cyanine dye and quantified with a separate scan-
ning procedure.
A recent technological development is the Illumina
BeadChip system
11,12 that utilizes an “array of arrays”for-
mat. Each array on the support contains thousands of
wells into which up to hundreds of thousands of beads
self-assemble in a random fashion.Specific 50-mer gene
sequences concatenated with an address sequence rec-
ognize the beads and attach to them.After bead assem-
bly,a hybridization-based procedure is used to map the
array,to determine which bead type resides in each well
of the array and to validate the performance of each
bead type.An advantage of this technology is that sev-
eral samples can be analyzed on the same chip,thus pre-
venting experimental artifacts across chips or dye label-
ing procedures. For example, the recent HumanRef-8
chip offers the possibility of screening eight different
samples in parallel.
Other commercial chip providers are Amersham
Biosciences,NimbleGen,Febit,and Applied Biosystems.
There are advantages and disadvantages of the above-
mentioned platforms regarding hybridization specificity,
sample target material needed, and other factors, as
pointed out in a recent review.
13
Historically,the first array technology was based on spot-
ted cDNAs.
14-16This technology is still extensively in use in
the academic sector,but also in pharmaceutical research
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Figure 1. A: False-color image generated from a two-color hybridization on a cDNA array.
17 B: Linearity between concentration and measured sig-
nal intensity is the underlying assumption of microarray data analysis. Whereas the expression ratio of genes B and C yield a valid mea-
sure of the concentration differences, the ratio of genes A and B is misleading because of nonlinear deviations in the low intensity region.
C: Histogram of the coefficient of variation for genes from simulated array images
26 using three different image analysis programs for
data analysis that can be classified as manual (red), semi-automatic (black) and fully automatic (green). The blue bars show the counts
for the simulated input data.
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8000that involves probe sets not covered by standard array for-
mats.cDNAs have a high variability in length (600 to 1500
bp) and are amplified using a polymerase chain reaction
(PCR).PCR products are then transferred to the surface
via contact printing by robotic devices (Figure 1a).
The implicit assumption of all microarray studies is that
the signal intensity measured with a specific probe is pro-
portional to the number of molecules of the respective
gene in the target sample.Changes in signal intensities
are interpreted as concentration changes. It should be
pointed out that the signal intensities are only crude esti-
mators for the actual concentrations,and the interpreta-
tion as concentration changes is only valid if the inten-
sity-concentration correspondence is approximately
linear.Microarray measurements often show deviations
from this assumption:for example,saturation effects;the
spot signals are above a limit that no longer allows the
detection of concentration changes or other nonlineari-
ties if the concentration of the gene is below the detec-
tion limit of a microarray (Figure 1b).
Whole-genome chips carry probes for (more or less) the
entire genome. These chips are used typically in the
beginning of a study when it is not clear what genes are
responsible for the drug response of certain groups of
patients (for example drug-sensitive and -resistant).For
diagnostic purposes specific theme (or custom) chips are
used that carry only a few marker genes.The use of cus-
tom microarrays for neuroscience applications has been
discussed recently.
18
There have been several studies comparing the perfor-
mance of microarray platforms.
19-22 Most of these studies
reveal a poor correlation in the global expression of the
genes. This might be due to several reasons, such as
hybridization sensitivity due to the different probe lengths,
different chemical treatments,and different statistical meth-
ods in the readout of the scanned images.A further issue is
the source of the probe sequences.Annotation and probe
design typically differ with the background sequence data-
base used by the provider.Currently,several competing col-
lections of transcript sequences are available,and serve as
the basis for probe annotation such as Unigene,Refseq,
LocusLink,ENSEMBL,etc.Furthermore,probe design of
the chip provider must be updated regularly.A recent study
showed the potential misinterpretation of experiments per-
formed with Affymetrix probe set assignments that are not
updated to the latest genome annotations,and reported a
30% to 50% discrepancy in final lists of differentially
expressed genes in several gene expression studies.
23
Inherent in most technology platforms is software to read
the digital image after the scanning process and to com-
pute for each gene representative the intensity value.
24,25
Image analysis methods can be grouped into three dif-
ferent classes:manual,semiautomated,and automated
methods.Simulation studies on systematically perturbed
artificial images have shown that the data reproducibil-
ity increases with the grade of automation of the software
(Figure 1c).
26 However, for “noisy” images that show a
very irregular structure,manual methods might be the
best choice.
Data analysis components
Analysis of expression data comprises several modules
that address different questions relevant for drug
response screening.
27The most important tasks are:
• to identify genes that are differentially expressed when
comparing two or more conditions (for example,groups
of patients resistant or sensitive to a certain drug)
• to identify common gene expression patterns that clas-
sify individuals accordingly
• to identify relevant pathways explaining the expression
patterns.
Regarding the complexity of the resulting information,
the major goal of data analysis is filtering the many thou-
sands of uninformative genes to a set of informative
markers,networks,and pathways that are relevant for the
problem under analysis (Figure 2a).
Data from microarray experiments typically come out in
the form of a table with raw data,ie,the measured inten-
sity values.This raw data is not easily comparable across
experimental replicates,so that some data preprocessing
(or normalization) is necessary.The task of normalization
is the elimination of influencing factors that are not due
to the probe-target interaction,such as labeling effects
(different dyes),background correction,pin effects (spot-
ting characteristics),outlier detection (cross-hybridiza-
tion of oligonucleotide-probes),etc,thus making signal
values comparable across different experiments (Figure
2b).Different algorithms and methods have been pro-
posed to fulfill these tasks.
28-34
The identification of differentially expressed genes between
two or more experimental conditions is typically based on
two-sample location tests.This setup utilizes replicated
experiments with independent samples.The power of such
tests is heavily dependent on the number of experimental
replicates (Figure 2c).These tests can be used to assign to
State of the art
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each single gene a P value that judges the significance of
the fold change.Here,it is notable that this P value is only
valid if the distributional assumptions are valid.For exam-
ple,if a Student’s t-test results in a significant P value,the
implication that the corresponding gene is differentially
expressed is only true if both sample series are Gaussian-
distributed and have equal variances. Usually, these
assumptions do not hold in practice but,strikingly,in most
studies this fact is entirely ignored.In our studies we rely
therefore on nonparametric alternatives
17,35 (Figure 2d):
Wilcoxon’s rank sum test is based on the ranks of the repli-
cates rather than on the actual signal values.This test (and
other tests based on linear rank statistics such as the van
der Waerden test) is preferable to the parametric t-tests if
the distributional assumptions cannot be proven to be
Gaussian. Furthermore, for “noisy” data this test yields
more robust results since it is less sensitive against outlier
values.For larger sample sizes,ie,>25 replicates,we can
approximate the P value of the Wilcoxon rank test by the
standard normal distribution. However, most practical
applications will be based on a rather smaller number of
observations (sample sizes in the order of 4 to 12).
Therefore,those P values must be calculated exactly.This
can be done using a recursive method.
36
Figure 2. A: Schematic description of the biomarker discovery process. B: Nonlinear dependencies of fold change (Y-axis) and signal strength (X-axis)
in raw data and LOWESS normalization for the compensation of these effects. This method fits the data sets by local polynomials using
weighted least squares.C: Dependency of detection power for expression differences (Y-axis) from the number of experimental replicates.
Different curves correspond to different expression ratios: 1.5 (black), 2 (red), 2.5 (green), 3 (blue), 5 (yellow) and 10 (magenta). D: Robust
statistical testing identifies even small expression changes (~1.5). Microarray expression changes (gray bars) verified by RT-PCR (red bars) in
mouse cortex (kindly provided by Marc Sultan and Marie-Laure Yaspo).
34 LOWESS, locally weighted polynomial regression
AB
Whole genome data
Marker filter level
Network filter level
Hypotheses
Pathway filter level
C
D
Sample size
T
r
u
e
 
p
o
s
i
t
i
v
e
 
r
a
t
e
0.0
01
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
2 3 4 5 6 7 8 9 10 11 12 13 14 15
LOWESS
RAW DATA
Cortex
0.0
1.0
2.0
3.0
4.0
5.0
U
s
p
2
5
J
a
m
2
A
t
p
5
a
A
p
p
U
s
p
1
6
S
o
d
1
S
o
d
1
S
y
n
j
1
I
l
1
0
r
b
S
o
n
S
o
n
A
t
p
5
o
M
r
p
s
6
C
2
1
o
r
f
5
1
C
2
1
o
r
f
5
1
C
b
r
1
C
b
r
1
C
b
r
1
D
s
c
r
5
D
s
c
r
2
D
s
c
r
2
H
m
g
n
1
B
a
c
e
2
M
x
2
P
t
t
g
1
i
p
K
i
a
a
0
1
8
4If several different experimental conditions are screened
(for example different time points after medical treat-
ment),then each gene expresses a certain numerical pro-
file across these conditions. Clustering algorithms are
explorative statistical methods that group together genes
with similar profiles and separate genes with dissimilar
profiles,whereby similarity (or dissimilarity) is defined
numerically by a pairwise (dis)similarity function such as
Euclidean distance or Pearson correlation.
37-40
Hierarchical clustering can be combined with a color-
coded representation of the signal values (the expression
patterns) and visualized in the form of a dendrogram.
Clustering is a very intuitive way of visualizing data,but
it should be pointed out that the dendrogram is strongly
dependent on the parameters chosen for cluster analysis.
Thus,each clustering process should undergo decent val-
idation.
41Associated groups of genes are usually further
investigated,for example for common binding sites in the
promoter sequences of the genes
42 or for common func-
tional content.
43
The major result of the explorative analysis is essentially
a list of potential marker genes relevant for the disease or
treatment under analysis.Since microarray data is error-
prone,this list contains a lot of false positives.Thus,further
filtering steps are commonly included in the analysis.
Recent methods therefore aim at the correlation of the
gene expression profiles with complementing sources of
data such as pathway annotation,gene ontology (GO) cat-
egories,sequence analysis,clinical data,etc.
44-46
Genes do not act as individual units;they collaborate in
overlapping pathways,the deregulation of which is a hall-
mark for the disease under study.New bioinformatics tools
have been developed that judge gene expression changes
in the context of such pathway analysis.We have devel-
oped a method that judges the alteration of entire path-
ways with respect to two experimental conditions.This has
been applied recently for the identification of pathways
altered upon differentiation of inner cell mass and tro-
phectoderm in the human blastocyst
47 and upon hormone-
induced aging of the human skin.
48The procedure is based
on pathway annotation (for example provided by the
Kyoto Encyclopedia of Genes and Genomes [KEGG]
pathway database).
49This information is then translated
into a two-dimensional statistical test problem that
involves Wilcoxon’s signed rank sum test in order to com-
pute a Z-score for each pathway that quantifies the degree
of alteration across the different experimental conditions.
The results of the pathway analysis in the latter study,for
example,implicate the involvement of several metabolic
pathways in the aging process, such as C21-steroid 
hormone metabolism, phospholipid degradation,
prostaglandin and leukotriene metabolism,2,4-dichloro-
benzoate degradation, and fatty acid biosynthesis.
Interestingly, pathways operative in neurodegenerative
disease such as Huntington's disease (HD),
50,51 denta-
torubral-pallidoluysian atrophy (DRPLA),
52 and amy-
otrophic lateral sclerosis (ALS)
53 also showed significant
age-dependent expression changes.
Databases, standardization initiatives, 
and common platforms
It has been recognized that there is a fundamental need
worldwide to share microarray data in order to correlate
researchers’ results with already published data.Since for
such a task it is necessary to provide the raw data,large
microarray databases have been set up as public reposi-
tories (for example the gene expression omnibus (GEO)
from NCBI
54 and ArrayExpress from EBI
55).
Functional annotation is provided by the GO consor-
tium.
56The aim of GO is to maintain a consistent,species-
independent,functional description of gene products.GO
terms have a defined parent-child relationship and form
a directed acyclic graph (DAG).At the root of the GO
are the three top-level categories—molecular function,
biological process,and cellular component—which con-
tain many levels of child nodes (GO terms) that describe
a gene product with increasing specificity.There are sev-
eral tools for mining these annotations.We have devel-
oped the GOblet server that computes GO-term graph
annotation for DNA sequences comprising several dif-
ferent sequence databases.
57,58
A particular data repository for neuroscience applica-
tions is the National Brain Databank,a publicly acces-
sible gene expression repository for the collection and
dissemination of results from postmortem studies of neu-
rological and psychiatric disorders.The project has been
developed by the Harvard Brain Tissue Resource Center
(HBTRC) in collaboration with Akaza Research,as an
online resource for the neuroscience community.
A further useful database for drug discovery and drug
response screening is PharmGKB.
59,60This database is a
central repository for genetic,genomic,molecular,and
cellular phenotype data and clinical information about
people who have participated in pharmacogenomics
research studies.The data includes,but is not limited to,
State of the art
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clinical and basic pharmacokinetic and pharmacoge-
nomic research in the cardiovascular,pulmonary,cancer,
pathway,metabolic,and transporter domains.Currently,
information on 385 drugs and 22 different pathways can
be reviewed.
Standardization and the development of standard oper-
ating procedures (SOPs),both for data generation and
data analysis,are major issues in community initiatives.
Whereas SOPs are widespread in experimental proce-
dures,they are not available for the data-analysis part.
Publications often report data analysis methods that are
hard to reproduce. Thus, it has been worthwhile to
develop some common analysis platforms.Besides com-
mercial programs there have been powerful open-source
platforms such as R/Bioconductor.These platforms con-
tain standard statistical procedures,visualization meth-
ods,and methods for importing and exporting data.In a
script-based language data analysis methods can be
reported and easily reproduced.
The “druggable genome”
The detection of genes (or compounds) that have a par-
ticular molecular feature that makes them useful for
measuring disease progression or effects of treatments
can be enhanced by microarray analysis,provided there
is a robust data analysis and correlation of the experi-
mental outcome.Other functional genomics technologies
are needed to complement the results obtained from
microarrays. These technologies (such as proteomics,
metabonomics,etc.) are inherent in standard drug screen-
ing workflows in pharmaceutical companies.
61 However,
the flood of data produced is not easily handlable,and
requires a new generation of computational tools that are
more effective in managing the data and are able to
embed the obtained result in a functional context.
62,63
Current treatments for most neurological disorders are
either ineffective or minimally effective or produce
severe side effects (for example antipsychotic medication
in schizophrenia
64,65).Thus,there is a clear need for better
methods.A potential direction could be the development
of compounds that effectively address the disease path-
ways driven by disease-related pathway identification
methods.
It has been reported that the number of potential drug
targets is fairly limited.An assessment of the number of
genes that might serve as potential targets for drugs has
been given recently.
66,67 Starting from the fact that there
are well-known properties that define good drugs, the
number of potential drug targets is predictable.These
properties can be summarized as
68:
• presence of more than five hydrogen-bond donors 
• molecular mass >500 d
• high lipophilicity
• more than 10 nitrogen and oxygen atoms.
These properties increase the likelihood of oral bioavail-
ability of a compound,ie,what makes it a commercially
viable drug.Looking at the binding sites on human protein
sequences for such compounds,only approximately 400
potential targets have been identified.Extending these tar-
gets to all members of their relevant gene families,approx-
imately 3000 molecular targets can be identified.Most of
these genes belong to a few gene families such as G pro-
tein coupled receptors (GPCRs), serine/threonine and
tyrosine protein kinases,and nuclear hormone receptors.
The implications of these estimations are that the limited
number of druggable targets will be well explored within
the next decade,with chemical leads being available for
most of them.Thus,there will be a shift from the develop-
ment of leads to the investigation of the molecular conse-
quences of the drug treatment in the individual patient.
Challenges in neuroscience applications
Drug discovery and treatment in neuroscience face spe-
cific challenges,in particular regarding the availability of
tissue,poor diagnosis,complexity of brain tissue,and the
lack of good model systems for drug target validation.
69
Tissue samples in neuroscience applications are mostly
post-mortem brain samples from affected individuals.
These samples typically reflect the end stage of the dis-
ease, which highly biases the material and makes it
impossible to study early disease stages.
70 Furthermore,
the patients have typically undergone some disease treat-
ment, which has an influence on the gene expression.
Thus,separating the effects of these treatments from the
effects of the disease is extremely difficult.Here,animal
models and tissue culture systems can help to identify
marker genes and pathways for the disease,as is common
in other studies.For example,in a recent work we have
utilized a mouse model (Ts65DN
71) for trisomy 21 in
order to identify genes that show dosage imbalances with
respect to aneuploidy.
29 Results for many genes (such as
APP) could be extrapolated to human tissue samples.
Good animal models allow the extraction of untreated
brain material as well as material from control samples.State of the art
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Rodent and (particularly) nonhuman primate models are
primarily interesting in this respect.
Current research utilizes microarrays in several areas of
neuroscience research, such as schizophrenia,
72,73 brain
cancer,
74 Alzheimer’s disease (AD),
75 and HD.
76 These
studies compare gene expression changes in patient and
control groups,and show that microarrays are valuable
tools for the expression profiling of drug response in
human individuals.
Interestingly,the latter study incorporated blood samples
from patients and control subjects and revealed changes
in blood mRNAs that reflect disease mechanisms
observed in HD brain.Moreover,these alterations cor-
relate with disease progression.For example,they were
able to identify genes altered in blood from HD patients
(such as ANXA, CAPZA1, HIF1A, P2Y5, SF3B1, SP3,
and TAF7) that were also differentially expressed in HD
postmortem brain. This work implies the potential of
using easily accessible tissue such as blood for monitor-
ing the progression of complex brain disorders.
Systems biology as a new research paradigm
Systems biology aims at the explanation of physiology
and disease from the level of interacting components
such as molecular pathways,regulatory networks,cells,
organs,and ultimately the entire organism.
77With the use
of computer models for such processes in silico predic-
tions can be generated on the state of the disease or the
effect of the individual therapy.The new approaches are
about to revolutionize our knowledge of disease mecha-
nisms and of the interpretation of data from high-
throughput technologies.
1
These approaches are necessary,considering the increas-
ing complexity of research.Often,several laboratories
are working with different techniques on the same prob-
lem.A fundamental challenge is thus to search through
the exhaustive set of data and extract meaningful infor-
mation.Here,in silico experiments can be the basis for a
more successful drug screening.
Furthermore,there is a fundamental need for integration
rules and methods.Multiple databases exist,a variety of
experimental techniques have produced gene and pro-
teome expression data from various tissues and samples,
and important disease-relevant pathways have been
investigated.Information on promoter regions and tran-
scription factors is available for many genes as well as
sequence information. This information—although
extremely helpful—cannot be utilized in a sufficient way
because of the lack of integrative analysis tools.A fun-
damental aim of systems biology is the understanding of
the underlying biological processes on the basis of this
data.
Crucial for the step from qualitative, explorative data
analysis to quantitative,predictive analysis is the com-
bination of experimental data with the knowledge of the
underlying biological reaction system. This approach
makes it possible to come up with conclusions about the
properties of the system,even those that are not subject
to experiments or are not even amenable by any experi-
mental approach. For this purpose we have developed
the modeling and simulation system PyBioS.
78With this
system it is possible to construct models that are based
on the topology of a cellular reaction network and ade-
quate reaction kinetics. Based on this information the
system can automatically construct a mathematical
model of differential equations that can be used for sub-
sequent simulation of the temporal behavior and model
analysis.Particularly,information on the topology of bio-
logical systems is available from several databases (eg,
KEGG).PyBioS provides interfaces to these databases
that can be used for the construction of appropriate
model prototypes.Models include metabolic pathways,
signal transduction pathways,transport processes,gene
regulatory networks,among others,and can be accessed
via a Web interface.
Mathematical models for disease pathways have been
developed,predominantly for cancer.Examples are gen-
eral emergence of properties of signaling pathways
79 such
as extended signal duration, threshold behaviors, etc,
endodermal growth factor receptor (EGFR) signaling,
80-82
and the TNF alpha-mediated NF-kappa B-signaling path-
way (NFκB).
83,84 Specific pathway models for neuro-
science applications are currently rare.Nevertheless,an
understanding of the dynamics of these diseases could
help to develop strategies to halt them at the stage they
have reached at detection,or to prevent them entirely.
85
Conclusion
Despite the great uncertainties inherent in functional
genomics techniques, they will be indispensable for
future work in drug development and therapy monitor-
ing.However,these techniques must be accompanied by
solid support from data analysis.Bioinformatics,and to
an increasing degree,systems biology,have key roles inExpression profiling of drug response - Herwig and Lehrach Dialogues in Clinical Neuroscience - Vol 8 . No.3 . 2006
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is restricted to the targeted molecular level and the pre-
cision of the experimental techniques in use. It is very
likely that the range of this experimental granularity will
increase in the coming years, utilizing heterogeneous
techniques that target a biological question of interest at
different points so that data integration becomes a major
challenge for future biomedical research.
In the case of complex disease conditions it is clear that
such integrated approaches are required in order to link
clinical,genetic,behavioral,and environmental data with
diverse types of molecular phenotype information and to
identify correlative associations. Such correlations, if
found, are the key to identifying biomarkers and
processes that are either causative or indicative of the
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In order to screen the success of drug treatment in the
individual patient,new generations of tools and research
methods will be developed.These tools will enable us to
perform the crucial step from qualitative to quantitative
analysis. Systems biology is pointing in this direction.
With its close connection of experimental data genera-
tion,predictive data modeling,and subsequent validation
it holds the promise of providing computational tools
capable of personalized treatment and therapy monitor-
ing in the individual patient. ❏
The authors wish to thank Christoph Wierling for proofreading the manu-
script and Sylvia Krobitsch for providing neuroscience literature.State of the art
292
33.Irizarry RA, Bolstad BM, Collins F, Cope LM, Hobbs B, Speed TP.
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res.
2003;31:e15.
34.Draghici S. Data Analysis Tools for DNA Microarrays. Boca Raton, Fla:
Chapman & Hall/CRC Press; 2003.
35.Kahlem P, Sultan M, Herwig R, et al. Transcript level alterations reflect
gene dosage effects across multiple tissues in a mouse model of Down syn-
drome. Genome Res. 2004;14:1258-1267.
36.Herwig R, Aanstad P, Clark M, Lehrach H. Statistical evaluation of dif-
ferential expression on cDNA nylon arrays with replicated experiments.
Nucleic Acids Res. 2001;29:E117.
37.Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and dis-
play of genome-wide expression patterns. Proc Natl Acad Sci U S A.
1998;95:14863-14868.
38.Tamayo P, Slonim D, Mesirov J, et al. Interpreting patterns of gene
expression with self-organizing maps: methods and application to
hematopoietic differentiation. Proc Natl Acad Sci U S A. 1998;96:2907-2912.
39.Herwig R, Poustka AJ, Müller C, Lehrach H, O'Brien J. Large-scale clus-
tering of cDNA fingerprinting data. Genome Res. 1999;9:1093-1105.
40.Sharan R, Shamir R. CLICK: a clustering algorithm with applications to
gene expression analysis. Paper presented at: Proceedings of the 8th
International Conference on Intelligent Systems for Molecular Biology
(ISMB); 2000; Menlo Park, California, USA.
41.Jain AK, Dubes RC. Algorithms for Clustering Data. Englewood Cliffs, NJ:
Prentice Hall;1988.
42.Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM. Systematic
determination of genetic network architecture. Nat Genet. 1999;22:281-
285.
El perfil de expresión de la respuesta a los 
fármacos: desde los genes a las vías 
involucradas
La comprensión de la respuesta individual a un fár-
maco –que determina su eficacia y tolerabilidad en
el organismo– es el principal cuello de botella en el
desarrollo actual de fármacos y ensayos clínicos. La
respuesta intracelular y el metabolismo, donde par-
ticipan por ejemplo las enzimas del citocromo P-450,
puede aumentar o disminuir el efecto de diferentes
fármacos, dependiendo de  la variante genética. La
tecnología de microarrays ofrece el potencial para
mapear la composición genética del paciente indivi-
dual. Sin embargo, como los experimentos no son
tan precisos deben acompañarse de un análisis sólido
y consistente de los datos. Además, la investigación
reciente apunta a la combinación de datos con meto-
dología proveniente de modelos matemáticos que
permiten una asistencia orientada a problemas en el
proceso de descubrimiento de fármacos. Este artículo
revisará el estado actual del conocimiento acerca de
las plataformas de tecnología de arrays de ADN y los
elementos básicos del análisis de los datos y la inves-
tigación bioinformática en el descubrimiento de fár-
macos. Para incrementar el análisis de un gen único,
se presentará un nuevo método para la interpreta-
ción de los cambios en la expresión de los genes
teniendo en cuenta todas las vías involucradas.
Además se introducirá el concepto de biología de sis-
temas, como un nuevo paradigma para el desarrollo
de fármacos, y se destacará nuestra reciente inves-
tigación acerca del desarrollo de un modelo y una
plataforma de simulación para aplicaciones biomé-
dicas. Finalmente se discutirán las potencialidades de
la biología de sistemas para los modelos de respuesta
a fármacos en el paciente individual. 
Profilage de l’expression de la réponse au
médicament : des gènes aux voies d’accès
La compréhension de la réponse individuelle au
médicament, ce qui détermine son efficacité et sa
tolérance chez le patient, est le principal goulet
d’étranglement des essais cliniques et du dévelop-
pement des médicaments actuels. Le métabolisme et
la réponse intracellulaires, par exemple à travers les
enzymes du cytochrome P-450, peut soit augmenter
soit diminuer l’effet des différents médicaments,
selon la génétique. Des microéchantillons (microar-
rays) permettent de déterminer la configuration
génétique de chaque patient. Ces techniques sont
toutefois imprécises, justifiant une méthodologie
précise et exigeante lors de l'analyse. De plus, la
recherche récente permet un débit élevé de données
avec des méthodes de modèlisation mathématique
permettant de résoudre les problèmes ayant trait aux
moyens de découverte des médicaments. Cet article
concerne les techniques de pointe des plates-formes
de technologie de microéchantillons d’ADN ainsi que
les bases de l’analyse de données et de la recherche
bio-informatique pour la découverte des médica-
ments. Nous présenterons une nouvelle méthode
consistant à décrire les modifications de l’expression
génétique au niveau de toute une cascade de
réponses biologiques. Nous introduirons le concept
de biologie des systèmes comme un nouveau para-
digme pour le développement des médicaments et
nous mettrons l’accent sur notre recherche récente,
le développement d’une plate-forme de simulation
et de modélisation pour les applications biomédi-
cales. Nous discuterons du potentiel de la biologie
des systèmes pour la modélisation de la réponse de
chaque patient au médicament. Expression profiling of drug response - Herwig and Lehrach Dialogues in Clinical Neuroscience - Vol 8 . No.3 . 2006
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